Women Leading Multiple Myeloma: Ciltacabtagene Autoleucel in Multiple Myeloma – Optimizing Sequencing, Safety Management, and Care Team Communication
This opening segment introduces a discussion on ciltacabtagene autoleucel (cilta-cel) in multiple myeloma and frames the questions the program sets out to answer: how chimeric antigen receptor (CAR) T-cell therapy should be sequenced among the available options, and how care can be coordinated across a network spread between referring practices and treating centers.
The faculty discuss how to individualize the choice between chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies in relapsed multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
